Medtronic launched its Viaverte basivertebral nerve ablation system and completed the acquisition of SPR Therapeutics, broadening its chronic pain offering across the care continuum. The combination adds a procedural option (BVNA) designed to target chronic pain drivers and strengthens Medtronic’s ability to treat patients at multiple stages of pain management. The announcement positions the company to compete in a category that is increasingly shifting toward disease-source and pathway-targeted interventions. For health systems and investors, the rollout highlights how large med-tech players are rebalancing portfolios toward interventions that may reduce reliance on opioid-centric care pathways.